Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab

por van Rhee, Frits, Rothman, Margaret, Ho, Kai Fai, Fleming, Sarah, Wong, Raymond S., Fosså, Alexander, Dispenzieri, Angela, Cavet, James, Munshi, Nikhil, Vermeulen, Jessica, Casper, Corey
Publicado 2015

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

por Johnson, Peter W. M., Balasubramanian, Sriram, Hodkinson, Brendan, Shreeve, S. Martin, Sun, Steven, Srinivasan, Srimathi, Steele, Andrew J., Vermeulen, Jessica, Sehn, Laurie H., Wilson, Wyndham H.
Publicado 2023

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

por van Rhee, Frits, Casper, Corey, Voorhees, Peter M., Fayad, Luis E., van de Velde, Helgi, Vermeulen, Jessica, Qin, Xiang, Qi, Ming, Tromp, Brenda, Kurzrock, Razelle
Publicado 2015

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

por Balasubramanian, Sriram, Hodkinson, Brendan, Schuster, Stephen J., Fowler, Nathan H., Trotman, Judith, Hess, Georg, Cheson, Bruce D., Schaffer, Michael, Sun, Steven, Deshpande, Sanjay, Vermeulen, Jessica, Salles, Gilles, Gopal, Ajay K.
Publicado 2021

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell ly...

por Zhu, Jun, Hong, Xiaonan, Song, Yu Qin, Hodkinson, Brendan, Balasubramanian, Sriram, Wang, Songbai, Zhang, Qingyuan, Shi, Yuankai, Huang, Huiqiang, Zhang, Huilai, Zhu, Yan, Shreeve, Stephen Martin, Sun, Steven, Wang, Ze, Wang, Xiaocan, Fan, Yue, Wilson, Wyndham, Vermeulen, Jessica
Publicado 2022

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial

por Minnema, Monique C., Dispenzieri, Angela, Merlini, Giampaolo, Comenzo, Raymond L., Kastritis, Efstathios, Wechalekar, Ashutosh D., Grogan, Martha, Witteles, Ronald, Ruberg, Frederick L., Maurer, Mathew S., Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Jaccard, Arnaud
Publicado 2022

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

por Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya, Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Richardson, Paul G., Voorhees, Peter
Publicado 2022

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

por Sborov, Douglas W., Baljevic, Muhamed, Reeves, Brandi, Laubach, Jacob, Efebera, Yvonne A., Rodriguez, Cesar, Costa, Luciano J., Chari, Ajai, Silbermann, Rebecca, Holstein, Sarah A., Anderson, Larry D., Kaufman, Jonathan L., Shah, Nina, Pei, Huiling, Patel, Sharmila, Cortoos, Annelore, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Voorhees, Peter M., Richardson, Paul G.
Publicado 2022

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase II...

por Hulin, Cyrille, Offner, Fritz, Moreau, Philippe, Roussel, Murielle, Belhadj, Karim, Benboubker, Lotfi, Caillot, Denis, Facon, Thierry, Garderet, Laurent, Kuhnowski, Frédérique, Stoppa, Anne-Marie, Kolb, Brigitte, Tiab, Mourad, Jie, Kon-Siong, Westerman, Matthijs, Lambert, Jérôme, Pei, Lixia, Vanquickelberghe, Veronique, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Sonneveld, Pieter, van de Donk, Niels W.C.J.
Publicado 2021

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

por Fokkema, Cathelijne, Moreau, Phillipe, van der Holt, Bronno, Lambert, Jérôme, van Duin, Mark, Wester, Ruth, Jongen, Joost L.M., van Doorn, Pieter A., Godet, Sophie, Jie, KonSiong, Fitoussi, Olivier, Delforge, Michel, Keita-Manta, Awa, Luycx, Odile, Cupedo, Tom, van de Donk, Niels W.C.J., Zweegman, Sonja, Vermeulen, Jessica T., Sonneveld, Pieter, Broijl, Annemiek
Publicado 2022

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

por Brown, Jennifer R., Moslehi, Javid, O’Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Kipps, Thomas J., Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F., Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A.
Publicado 2017

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

por Kraeber-Bodéré, Françoise, Zweegman, Sonja, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Facon, Thierry, Leleu, Xavier, Belhadj, Karim, Itti, Emmanuel, Karlin, Lionel, Bailly, Clément, Levin, Mark-David, Minnema, Monique C., Jamet, Bastien, Bodet-Milin, Caroline, de Keizer, Bart, Béné, Marie C., Avet-Loiseau, Hervé, Sonneveld, Pieter, Pei, Lixia, Rigat, Fabio, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Lambert, Jérôme, Moreau, Philippe
Publicado 2022